Search
Search Results
-
Comparison of hyperthermic intravesical chemotherapy and Bacillus Calmette–Guerin therapy in high-risk non-muscle invasive bladder cancer: a matched-pair analysis
PurposeTo compare adjuvant hyperthermic intravesical chemotherapy (HIVEC) with mitomycin C and standard Bacillus Calmette–Guerin (BCG) therapy in...
-
Device-assisted intravesical chemotherapy versus bacillus Calmette–Guerin for intermediate or high-risk non-muscle invasive bladder cancer: a systematic reviewer and meta-analysis
PurposeTo investigate the effectiveness and safety of device-assisted intravesical chemotherapy compared to Bacillus Calmette–Guerin (BCG) in the...
-
Seminal papers in urology: maintenance Bacillus Calmette-Guerin (BCG) immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study (SWOG-8507)
The South West Oncology Group’s 2000 randomised-control trial investigated the addition of maintenance intravesical bacillus Calmette-Guerin (BCG) to...
-
Bacillus Calmette Guerin (BCG) Immunotherapy for Bladder Cancer: A Control and Mathematical Analysis
In this manuscript, Immunotherapy with Bacillus Calmette Guerin (BCG) vaccine is devised for treating spherical bladder cancer. We considered the...
-
Adjuvant Intravesical Therapy: Bacillus Calmette-Guerin
Bacillus Calmette-Guerin (BCG) is the first immunotherapy used in urology and is currently recommended by international guidelines for intermediate-...
-
Elicitation of Health State Utilities Associated with Progression from Bacillus Calmette-Guerin (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)
ObjectivesThe treatments for high-grade non-muscle invasive bladder cancer (NMIBC) vary between bladder preserving intravesical approaches and...
-
Intravesical Bacillus Calmette-Guerin treatment-induced sleep quality deterioration in patients with non-muscle invasive bladder cancer: functional outcome assessment based on a questionnaire survey and actigraphy
PurposeWe investigated sleep parameters and patient-reported outcomes before, during, and after induction Bacillus Calmette-Guerin therapy using...
-
Association between urine 6-sulfatoxy-melatonin level and intravesical Bacillus Calmette-Guerin treatment–induced sleep quality deterioration in patients with non-muscle invasive bladder cancer
PurposeThe level of 6-sulfatoxy-melatonin (SaMT), a metabolite of melatonin, in first-void morning urine reflects blood melatonin levels from the...
-
Nanocages engineered from Bacillus Calmette-Guerin facilitate protective Vγ2Vδ2 T cell immunity against Mycobacterium tuberculosis infection
Tuberculosis (TB), induced by Mycobacterium tuberculosis (Mtb) infection, remains a top killer among infectious diseases. While Bacillus...
-
Bacillus Calmette-Guerin (BCG) Vaccine Impact on Dementia Risk in Bladder Cancer Patients: A Systematic Review and Meta-Analysis
BackgroundThe BCG vaccine has been traditionally administered to prevent TB. It has been additionally used in bladder cancer patients as a therapy...
-
Analysis of risk factors for post-bacillus Calmette–Guerin-induced prostatitis in patients with non-muscle invasive bladder cancer
The objective of this study was to evaluate risk factors for bacillus Calmette–Guerin-induced prostatitis in patients with non-muscle invasive...
-
Bacillus Calmette–Guerin (BCG) Vaccine-associated Complications in Immunodeficient Patients Following Stem Cell Transplantation
PurposeBacillus Calmette–Guerin (BCG) is a live attenuated vaccine with the potential of causing severe iatrogenic complications in patients with...
-
Bacillus Calmette-Guérin (BCG)-Induced Protection in Brain Disorders
The Bacille Calmette-Guerin (BCG) vaccine is one of the most widely used vaccines in the world for the prevention of tuberculosis. Its immunological...
-
Reactive Arthritis following Bacillus Calmette–Guerin Therapy for Bladder Cancer: a Systematic Literature Review
Purpose of ReviewIntravesical BCG therapy (ivBCG) is a treatment for bladder cancer that complements surgery and prevents tumor progression. Reactive...
-
Intravesical Bacillus Calmette-Guerin (BCG) Therapy for Non-muscle Invasive Bladder Cancers: Long-term Results of a Modified Schedule
Intravesical BCG therapy is an integral part of management of non-muscle invasive bladder cancers. Our aim is to analyze the non-muscle invasive...
-
Post-Bacille Calmette–Guerin surveillance for non-muscle invasive bladder cancer: do random biopsies offer an advantage?
BackgroundThe optimal surveillance method for recurrence of non-muscle invasive bladder cancer (NMIBC) after intravesical BCG treatment is unknown....
-
Bacillus Calmette Guerin (BCG) Balanitis: a Rare Organ Complication of Non-muscle Invasive Urinary Bladder Cancer Following Intravesical Immunotherapy
Bacillus Calmette Guerin (BCG) is widely used for prevention of recurrence and progression in non-muscle invasive urinary bladder cancers. However,...
-
Nano-Bacillus Calmette-Guérin immunotherapies for improved bladder cancer treatment
Cancer immunotherapy has rapidly become the fourth mainstream treatment alternative after surgery, radiotherapy, and chemotherapy, with some...